Manufacturing

Articles

The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.

Avid Bioservices Enters Manufacturing Agreement with Humanigen for Lenzilumab

Using rDNA technology to synthesize production of proteins and peptide hormones, the biotech startup has achieved synthetic production of insulin, potentially lowering insulin cost by 30%. 

rBIO Hits Key Lab Milestone with Synthetic Production of Insulin

The grant will support the advancement of glycoengineering technology for plant-derived proteins developed by a University of Alberta scientist partnered with PlantForm.

NSERC Awards Alliance Grant to PlantForm to Enable Commercial-Scale Production of Protein Therapeutics

Jennifer Markarian is manufacturing editor of Pharmaceutical Technology.

Pharmaceutical Technology spoke with Tania Pereira Chilima, Deputy CTO at Univercells Technologies about their technology and how it can be used in viral vector manufacturing, which is needed for production of some of the COVID-19 vaccine candidates. 

Intensifed Process Offers Cost-Effective Viral Vector Manufacturing

The new super plant, being built in Incheon, South Korea, will have a total biopharmaceutical manufacturing capacity of 256,000 L.

Samsung Biologics Begins Construction on Fourth Biopharma Manufacturing Plant 

The companies have formed a long-term manufacturing agreement to accelerate the global supply for Lilly’s COVID-19 antibody therapeutics.

Samsung Biologics and Lilly Partner to Accelerate Delivery of COVID-19 Antibody Therapeutics

The agreement follows a recent announcement that Sartorius plans to invest $100 million in Songdo, South Korea’s bio cluster.

Samsung Biologics Signs MOU with Sartorius to Enhance Supply Chain for Biomedicines

Sanofi’s Digitally Enabled Integrated Continuous Biomanufacturing Facility in Framingham, MA was named the Overall Award winner at the ISPE virtual annual meeting. 

Sanofi Wins ISPE FOYA Overall Award

The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19, at Lonza's Portsmouth, NH site.

Lonza to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination

The new VirusExpress lentiviral production platform increases dose yields and reduces process development time for cell and gene therapies.

Manufacturing, Biologic Drugs